| Name | MDR-1339 |
| Description | MDR-1339 (DWK-1339) is an orally active, blood-brain-barrier-permeable inhibitor of amyloid-β (Aβ) aggregation. |
| In vitro | MDR-1339 shows no significant inhibition of a panel of CYP isozymes, while it slightly inhibits CYP2C8 (IC50: 31.4 μM). MDR-1339 (1.5-10 μM) protects cells from this Aβ-induced toxicity. MDR-1339 (3.1-50 μM) also dose-dependently blocks the formation of Aβ aggregates and disaggregates Aβ fibrils. |
| In vivo | MDR-1339 (0.1-10 mg/kg, p.o.) dose-dependently restores passive avoidance responses in Alzheimer's disease mice models (ED50: 0.19 mg/kg) and significantly improves spontaneous alternation while reducing Aβ1-40 and Aβ1-42 levels in APP/PS1 mice at 30 and 100 mg/kg, p.o. daily for 8 weeks. |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | DMSO : 40 mg/mL (122.55 mM), Sonication is recommended. 10% DMSO+90% Corn Oil : 2 mg/mL (6.13 mM), Sonication is recommended.
|
| Keywords | β-amyloid peptide | βAmyloid | β Amyloid | MDR-1339 | MDR1339 | MDR 1339 | Inhibitor | inhibit | Gammasecretase | DWK1339 | DWK 1339 | BetaAmyloid | Beta Amyloid | bAmyloid | b Amyloid | Aβ | Amyloid-β | Abeta |
| Inhibitors Related | Benzenesulfonamide | Deferoxamine Mesylate | HEPPS | Phytic acid sodium salt | Rutin | Valproic Acid | 10-Undecenoic acid | 2,4-Di-tert-butylphenol | Chlorzoxazone | Prednisone acetate | Methyl tridecanoate | Glimepiride |
| Related Compound Libraries | Anti-Neurodegenerative Disease Compound Library | Bioactive Compound Library | Anti-Alzheimer's Disease Compound Library | Neuronal Signaling Compound Library | ReFRAME Related Library | Drug Repurposing Compound Library | CNS-Penetrant Compound Library | Inhibitor Library | Stem Cell Differentiation Compound Library | Orally Active Compound Library | Clinical Compound Library | Bioactive Compounds Library Max |